<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4565">
  <stage>Registered</stage>
  <submitdate>31/07/2014</submitdate>
  <approvaldate>31/07/2014</approvaldate>
  <nctid>NCT02206802</nctid>
  <trial_identification>
    <studytitle>Minoxidil Response Testing in Females With Female Pattern Hair Loss</studytitle>
    <scientifictitle>Minoxidil Response Testing in Females With Female Pattern Hair Loss</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>AB-IVD-MINOXIDIL-004</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Alopecia</healthcondition>
    <healthcondition>Female Pattern Hair Loss</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Autoimmune diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - 5% minoxidil topical foam

Predicted as non-responders - Patients that the minoxidil response in-vitro diagnostic kit predicted as non-responders. 5% minoxidil topical foam will be administered to subjects in this group.

Predicted as responders - Patients that the minoxidil response in-vitro diagnostic kit predicted as responders. 5% minoxidil topical foam will be administered to subjects in this group.


Treatment: drugs: 5% minoxidil topical foam
5% minoxidil topical foam

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Sensitivity and specificity of the minoxidil response in-vitro diagnostic kit to predict at baseline the change in Target Area Hair Count - Number of hairs measured in the target area by macrophotography.</outcome>
      <timepoint>baseline to week 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Sensitivity and specificity of the minoxidil response in-vitro diagnostic kit to predict at baseline the subjects ratings</outcome>
      <timepoint>baseline to week 24</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Sensitivity and specificity of the minoxidil response in-vitro diagnostic kit to predict at baseline the change in Target Area Hair Count - Number of hairs measured in the target area by macrophotography.</outcome>
      <timepoint>baseline to week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Sensitivity and specificity of the minoxidil response in-vitro diagnostic kit to predict at baseline the treatment efficacy evaluated by expert panel review of global photographs assessing hair regrowth</outcome>
      <timepoint>baseline to week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Sensitivity and specificity of the minoxidil response in-vitro diagnostic kit to predict at baseline the mean change in non-vellus hair diameter in the target region</outcome>
      <timepoint>baseline to week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change in minoxidil sulfotransferase activity in plucked hairs as measured by the minoxidil response in-vitro diagnostic kit</outcome>
      <timepoint>baseline to week 24</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Females in overall good health

          -  Age: 18 or older

          -  Female pattern hair loss

          -  Willing to have a mini dot tattoo placed in the target area of the scalp

          -  Willing to maintain the same hair style, color, shampoo and hair products use, and
             approximate hair length throughout the study

          -  Able to give informed consent

          -  Able to comply with the study requirements for 24 consecutive weeks

          -  Willing to use an adequate method of birth control (if applicable)

          -  Negative urine pregnancy test</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Previous adverse event from topical minoxidil treatment

          -  History of hypotension

          -  Uncontrolled hypertension

          -  Pregnant, nursing, or planning a pregnancy during the study

          -  Prior hair transplant

          -  Uses wigs or hair weaves

          -  Have used minoxidil (topical or oral) anytime during the past 6 months

          -  Chronic scalp disorders that require medications

          -  Uses medication known to cause hair thinning such as Coumadin and
             anti-depressants/anti-psychotics

          -  Folliculitis

          -  Scalp psoriasis

          -  Seborrheic dermatitis

          -  Inflammatory scalp conditions such as lichen planopilaris

          -  Enrolled in any other medical study or has been enrolled in any medical study in the
             past 6 months</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>300</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Sinclair Dermatology - East Melbourne</hospital>
    <postcode>3002 - East Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Mumbai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Florence</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Applied Biology, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of this study is to evaluate the clinical validity of the minoxidil
      response in-vitro diagnostic kit.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02206802</trialwebsite>
    <publication>Roberts J, Desai N, McCoy J, Goren A. Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil in the treatment of female androgenetic alopecia. Dermatol Ther. 2014 Jul-Aug;27(4):252-4. doi: 10.1111/dth.12130. Epub 2014 Apr 28.
Goren A, Castano JA, McCoy J, Bermudez F, Lotti T. Novel enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia. Dermatol Ther. 2014 May-Jun;27(3):171-3. doi: 10.1111/dth.12111. Epub 2013 Nov 27.
Buhl AE, Waldon DJ, Baker CA, Johnson GA. Minoxidil sulfate is the active metabolite that stimulates hair follicles. J Invest Dermatol. 1990 Nov;95(5):553-7.
Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004 Feb;150(2):186-94. Review.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sharon Keene, MD</name>
      <address>Physicians Hair Institute</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>